Xevinapant (Debio 1143, AT-406, 89), as displayed in Figure 19, an effective chemo-radio-sensitizer as a first-in-class oral IAP antagonist, currently being assessed in phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck (SCCHN), was recently proved to reverse HIV-1 latency in various latently infected T cell lines via the induction of a non-canonical NF-κB pathway, resulting in the enhancement of HIV-1 transcription [101]. Here, NFKB1 is linked to head and neck squamous cell carcinoma.